• Explore /
  • Poster
  • / A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer.

A first-in-human phase 1b study of a novel allosteric extracellular FGFR2 inhibitor alofanib in patients with refractory metastatic gastric cancer.

Abstract Video & Slides Poster

Authors

null

Sergei Tjulandin

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation

Sergei Tjulandin , Galina Statsenko , Elena Artamonova , Liubov Yu Vladimirova , Natalia Besova , Anastasia Mochalova , Ivan Rykov , Vladimir Moiseyenko , Igor A. Utyashev , Sergei Iugai , Vasily Kazey , Grigory Raskin , Nadezhda Dragun , Dmitry Reznikov , Evgenia Gavrilova , Ilya Tsimafeyeu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04071184

DOI

10.1200/JCO.2022.40.4_suppl.304

Abstract #

304

Poster Bd #

F8

Abstract Disclosures

Similar Posters

First Author: Krish Patel

First Author: Ilya Tsimafeyeu

First Author: Wen Wee Ma

First Author: Johann S. De Bono